CCS
UTHR icon

Crosspoint Capital Strategies’s United Therapeutics UTHR Stock Holding History

Crosspoint Capital Strategies’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-47
Closed -$6K – 773
2015
Q4 		$6K Sell
47
-114
-71% -$16.6K ﹤0.01% 787
2015
Q3 		$21K Sell
161
-478
-75% -$76.7K 0.02% 345
2015
Q2 		$111K Buy
639
+6
+0.9% +$1.08K 0.03% 260
2015
Q1 		$109K Buy
633
+396
+167% +$60.4K 0.05% 194
2014
Q4 		$31K Buy
+237
New +$30.5K 0.01% 393

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Crosspoint Capital Strategies's UTHR Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of United Therapeutics (UTHR) in Q1 2016, closing a stake of 47 shares — an estimated $6K sold.

Crosspoint Capital Strategies first reported a position in UTHR in Q4 2014 and held it in 5 quarters. The position peaked at $111K in Q2 2015. 398 funds tracked by Wall St. Rank hold UTHR as of Q1 2016.

  • Crosspoint Capital Strategies reported no remaining United Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 47 United Therapeutics shares in Q1 2016, an estimated $6K.
  • Crosspoint Capital Strategies first reported a position in United Therapeutics in Q4 2014 and held it in 5 quarters.
  • Crosspoint Capital Strategies's United Therapeutics position peaked at $111K in Q2 2015.
  • 398 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.